EXACT Sciences Co. (NASDAQ:EXAS) gapped down prior to trading on Tuesday . The stock had previously closed at $67.50, but opened at $68.25. EXACT Sciences shares last traded at $69.28, with a volume of 47945 shares trading hands.
EXAS has been the subject of a number of research reports. UBS Group initiated coverage on shares of EXACT Sciences in a research report on Tuesday, October 9th. They issued a “buy” rating and a $100.00 price target for the company. Cowen boosted their price target on shares of EXACT Sciences from $65.00 to $100.00 and gave the company an “outperform” rating in a research report on Wednesday, September 5th. Bank of America boosted their price target on shares of EXACT Sciences from $68.00 to $92.00 and gave the company a “buy” rating in a research report on Thursday, September 6th. BidaskClub cut shares of EXACT Sciences from a “buy” rating to a “hold” rating in a research report on Friday, September 14th. Finally, Robert W. Baird boosted their price target on shares of EXACT Sciences from $74.00 to $85.00 and gave the company an “outperform” rating in a research report on Tuesday, September 11th. Four investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. EXACT Sciences has an average rating of “Buy” and an average target price of $84.08.
The company has a debt-to-equity ratio of 0.94, a quick ratio of 11.72 and a current ratio of 12.08. The company has a market cap of $9.17 billion, a P/E ratio of -70.11 and a beta of 1.21.
In other EXACT Sciences news, insider D Scott Coward sold 2,190 shares of EXACT Sciences stock in a transaction on Monday, October 1st. The shares were sold at an average price of $79.51, for a total value of $174,126.90. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Graham Peter Lidgard sold 38,311 shares of EXACT Sciences stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $75.01, for a total transaction of $2,873,708.11. Following the completion of the transaction, the insider now owns 29,398 shares in the company, valued at $2,205,143.98. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 218,255 shares of company stock worth $15,791,740. 3.20% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Cornerstone Wealth Management LLC acquired a new position in shares of EXACT Sciences during the second quarter worth about $182,000. Chicago Partners Investment Group LLC increased its stake in shares of EXACT Sciences by 47.6% during the third quarter. Chicago Partners Investment Group LLC now owns 3,100 shares of the medical research company’s stock worth $191,000 after acquiring an additional 1,000 shares during the period. Hartford Investment Management Co. acquired a new position in shares of EXACT Sciences during the second quarter worth about $202,000. Fulton Bank N.A. acquired a new position in shares of EXACT Sciences during the third quarter worth about $208,000. Finally, Alps Advisors Inc. acquired a new position in shares of EXACT Sciences during the second quarter worth about $210,000. Institutional investors own 87.58% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.chaffeybreeze.com/2018/11/13/exact-sciences-exas-shares-gap-down-to-68-25.html.
EXACT Sciences Company Profile (NASDAQ:EXAS)
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.
Further Reading: Discover Your Risk Tolerance
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.